Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, Inc., and EMBO today announced that EMBO Molecular Medicine will, as of March 2012, join the Wiley Open Access publishing program. Articles in the journal will be open access and free to view, download and share for non-commercial use.
Since its launch in 2009, EMBO Molecular Medicine has attracted extremely high quality submissions and attained a first Impact Factor of 8.833, placing it 6th in the Medicine Research and Experimental ISI Category. With its emphasis on translational medicine, the studies published in EMBO Molecular Medicine are of interest to a wide spectrum of researchers, clinicians and the public. Converting to open access allows all readers to benefit from the high-level research advances reported in EMBO Molecular Medicine, aiding the dissemination of biomedical research and accelerating discovery.
EMBO Molecular Medicine was the recipient of the 2009 PROSE Award for Best Journal/ Science, Technology and Medicine.
Dr. Stefanie Dimmeler, Chief Editor of EMBO Molecular Medicine and Director of the Institute of Cardiovascular Regeneration at the Center for Molecular Medicine, Goethe University, Frankfurt, noted,“EMBO Molecular Medicine meets an important need in the scientific community by reporting the very latest advances in clinical science and basic research. Open access publishing of articles in EMBO Molecular Medicine will enhance the visibility of the journal and provide even greater reach for our published articles.”
Dr. Bernd Pulverer, Head of Scientific Publications at EMBO, said,“EMBO Molecular Medicine publishes important scientific discoveries with direct impact on clinical medicine and we are therefore particularly pleased to be in a position to increase access to this cutting edge research. EMBO Molecular Medicine is one of the highest profile biomedical journals to have converted to the Open Access model.”
David Nicholson, Vice President and Journals Publishing Director for Life Sciences at Wiley-Blackwell, commented: “We are delighted to be working with our partners at EMBO on the conversion of EMBO Molecular Medicine to a full open access arrangement. The journal has had a great impact in the community so far, and we are looking forward to building on this success as part of our growing activities in open access publishing.”
The journal is supported by the professional editors Anneke Funk and Céline Carret and an eminent international panel of Senior Editors, Drs. Dario Alessi, Giulio Cossu, Uta Francke, Fred Gage, Matthias Hentze, Edison T. Liu, Philippe Sansonetti and Bart de Strooper.
EMBO Molecular Medicine will publish all future articles under an Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0) Creative Commons License, which permits use, distribution, reproduction and adaptation in any medium, provided the original work is properly cited and is not used for commercial purposes. A publication fee will be payable by authors or their funder on acceptance of their primary research articles.
Please visit EMBO Molecular Medicine's website for further information.
EMBO Molecular Medicine is published by Wiley-Blackwell on behalf of EMBO.
Founded in 1807, John Wiley & Sons, Inc. (wiley.com) has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Our core businesses publish scientific, technical, medical, and scholarly (STMS) journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online applications and Websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Website can be accessed at wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
Wiley-Blackwell is the international STMS publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit wileyblackwell.com/ or our online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world’s most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.
About Wiley Open Access
Wiley Open Access, announced in February 2011, provides authors wishing to publish their research outcomes in an open access journal with a range of new high quality publications which meet the requirements of funding organizations and institutions where these apply. Wiley Open Access journals are supported by a network of high-quality journals and societies as well as internationally-renowned editorial board members.
EMBO (embo.org) stands for excellence in the life sciences. The organization enables the best science by supporting talented researchers, stimulating scientific exchange and advancing policies for a world-class European research environment.
EMBO is an organization of 1500 leading life scientist members that fosters new generations of researchers to produce world-class scientific results. EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in cutting-edge techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.